Cytek Biosciences (CTKB) Total Liabilities (2020 - 2026)

Cytek Biosciences' Total Liabilities history runs 7 years deep, the most recent figure standing at $121.5 million for Q1 2026.

• Quarterly Total Liabilities rose 17.96% year-over-year to $121.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.5 million (up 17.96% YoY) and the FY2025 annual result came in at $119.8 million, up 15.46% from the prior year.
• Total Liabilities was $121.5 million for Q1 2026 at Cytek Biosciences, up from $119.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $121.5 million in Q1 2026 and bottomed at $78.4 million in Q1 2022.
• A 5-year average of $101.4 million and a median of $101.4 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 74.01% — and 2024, when it declined 6.22%.
• Cytek Biosciences' Total Liabilities stood at $93.9 million in 2022, then advanced by 7.95% to $101.4 million in 2023, then grew by 2.34% to $103.8 million in 2024, then rose by 15.46% to $119.8 million in 2025, then increased by 1.39% to $121.5 million in 2026.
• Business Quant data shows CTKB's Total Liabilities at $121.5 million in Q1 2026, $119.8 million in Q4 2025, and $116.3 million in Q3 2025.